Regeneron Pharmaceuticals (NASDAQ: REGN) reported a 4% decline in earnings for the first quarter of 2019 due to higher costs and expenses.
Regeneron Pharmaceuticals (Nasdaq: REGN) will be reporting earnings for the first quarter Tuesday before the opening bell. Market watchers are of the
Regeneron Pharmaceuticals Inc. (REGN) reported a 371% jump in earnings for the fourth quarter helped by higher product sales and an income
Regeneron Pharmaceuticals Inc. (REGN) surpassed market expectations on revenue and earnings for the third quarter of 2018. The stock was up over